BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 26, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that management will present a corporate
overview at the NobleCon13 - Noble Capital Markets’ Thirteenth Annual
Investor Conference at the Boca Raton Resort & Club in Boca Raton,
Florida, on Monday, January 30, at 11:00 a.m. Eastern Standard Time.
A high-definition video webcast of BioTime’s presentation and a copy of
the presentation will be available at noblemediasite.com
and on the Company's web site at www.biotimeinc.com.
Microsoft’s SilverLight
viewer will be needed to participate. The webcast and presentation
will be archived on BioTime’s website at www.biotimeinc.com
following the event.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells. Pluripotent cells are capable of becoming
any of the cell types in the human body. Pluripotent cells have
potential application in many areas of medicine with large unmet patient
needs, including various age-related degenerative diseases and
degenerative conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
LinkedIn,
Facebook,
YouTube,
and Google+.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170126005421/en/
Source: BioTime, Inc.
Investor Contact:
EVC Group, Inc.
Matt Haines,
917-733-9297
mhaines@evcgroup.com
or
Media
Contact:
Gotham Communications, LLC
Bill Douglass,
646-504-0890
bill@gothamcomm.com